CLINICAL TRIALS PROFILE FOR BENDEKA
✉ Email this page to a colleague
All Clinical Trials for BENDEKA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01286272 ↗ | Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma | Active, not recruiting | National Cancer Institute (NCI) | Phase 2 | 2011-04-08 | This randomized phase II trial studies how well ofatumumab and bendamustine hydrochloride with or without bortezomib works in treating patients with untreated follicular non-Hodgkin lymphoma. Monoclonal antibodies, such as ofatumumab, may block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Bortezomib may also stop the growth of cancer cells by blocking blood flow to the tumor. It is not yet known whether ofatumumab and bendamustine hydrochloride are more effective with bortezomib in treating patients with follicular non-Hodgkin lymphoma. |
| NCT01754402 ↗ | Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma | Active, not recruiting | Celgene | Phase 1/Phase 2 | 2013-01-07 | This study is designed as a phase I-II, open label, dose finding study. Study treatment will be as follows, in 28 day cycles: - Pomalidomide: once daily orally (PO) dosing on days 1-21, every 28 days - Bendamustine: once intravenously (IV) dosing on day 1, every 28 days - Dexamethasone: weekly PO or IV dosing on days 1, 8, 15, and 22. After completing 6 cycles of treatment, dexamethasone may be decreased to 20mg per investigator discretion. After completing 12 cycles of treatment, patients will proceed to the maintenance phase of the study. Patients will receive Pomalidomide on day 1-21, every 28 days and dexamethasone on days 1, 8, 15, and 22 every 28 days until time of progression. |
| NCT01754402 ↗ | Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma | Active, not recruiting | Cristina Gasparetto | Phase 1/Phase 2 | 2013-01-07 | This study is designed as a phase I-II, open label, dose finding study. Study treatment will be as follows, in 28 day cycles: - Pomalidomide: once daily orally (PO) dosing on days 1-21, every 28 days - Bendamustine: once intravenously (IV) dosing on day 1, every 28 days - Dexamethasone: weekly PO or IV dosing on days 1, 8, 15, and 22. After completing 6 cycles of treatment, dexamethasone may be decreased to 20mg per investigator discretion. After completing 12 cycles of treatment, patients will proceed to the maintenance phase of the study. Patients will receive Pomalidomide on day 1-21, every 28 days and dexamethasone on days 1, 8, 15, and 22 every 28 days until time of progression. |
| NCT01886872 ↗ | Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia | Active, not recruiting | National Cancer Institute (NCI) | Phase 3 | 2013-12-09 | This randomized phase III trial studies rituximab with bendamustine hydrochloride or ibrutinib to see how well they work compared to ibrutinib alone in treating older patients with previously untreated chronic lymphocytic leukemia. Monoclonal antibodies, such as rituximab, may block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether rituximab with bendamustine hydrochloride may work better than rituximab and ibrutinib or ibrutinib alone in treating chronic lymphocytic leukemia. |
| NCT02153580 ↗ | Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia | Active, not recruiting | National Cancer Institute (NCI) | Phase 1 | 2014-09-24 | This phase I trial studies the side effects and best dose of cellular immunotherapy following chemotherapy in treating patients with non-Hodgkin lymphomas, chronic lymphocytic leukemia, or B-cell prolymphocytic leukemia that has come back. Placing a modified gene into white blood cells may help the body build an immune response to kill cancer cells. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for BENDEKA
Condition Name
Clinical Trial Locations for BENDEKA
Trials by Country
Clinical Trial Progress for BENDEKA
Clinical Trial Phase
Clinical Trial Sponsors for BENDEKA
Sponsor Name
